Deals & Corporate Governance

  • July 22, 2026

    Fannie Mae Drops $28M Suit Over Senior Living Loans Default

    Fannie Mae has voluntarily dropped the remaining claims in its lawsuit accusing borrower Affinity Living Communities of defaulting on $28.3 million worth of loans from the government-backed lender, telling the court the appointed receivership had achieved its purpose.

  • July 22, 2026

    Boston Scientific Settles With Stryker In Spine Device IP Fight

    Boston Scientific and Stryker Corp. have reached a settlement to resolve a case in New Jersey federal court over Stryker's alleged efforts to create a back pain device that infringed a Boston Scientific patent.

  • July 22, 2026

    Safety-Net Clinics Defend Insulin Suit Revival To Justices

    Safety-net healthcare providers urged the U.S. Supreme Court not to take on the revival of their proposed antitrust class action against Sanofi-Aventis, Eli Lilly, Novo Nordisk and AstraZeneca, arguing Wednesday that the Second Circuit's decision was based on neither mere trade group lobbying nor any kind of price-fixing.

  • July 22, 2026

    Candid Health Wraps $120M Series D Funding Round

    Autonomous revenue cycle management platform Candid Health, advised by Lowenstein Sandler LLP, on Wednesday revealed that it raised $120 million in its latest funding round, marking a three-times increase in valuation over the San Francisco-based company's previous funding round in February 2025.

  • July 22, 2026

    Fed. Circ. Panel Stands By Invalidated Spinal Fusion IP

    The Federal Circuit on Wednesday said it won't rethink a panel's decision invalidating patent claims covering parts used to make expandable implant devices in spinal fusion surgeries that were the basis of a $9.5 million jury verdict against Life Spine Inc.

  • July 21, 2026

    This Week's Healthcare Earnings: UnitedHealth, J&J, Elevance

    Payors UnitedHealth and Elevance and pharma giant Johnson & Johnson all raised their 2026 guidance after positive second quarters. Law360 has what you need to know from earnings this week.

  • July 21, 2026

    Wyeth's Patent Loss Has Attys Focusing On Dosage

    The Federal Circuit's holding that a Pfizer unit's cancer treatment patents are invalid highlights the risk of including dosages in patents without sufficient proof that those dosages work, attorneys say.

  • July 17, 2026

    Taxation With Representation: Freshfields, Slaughter And May

    In this week's Taxation With Representation, Uber Technologies Inc. buys food delivery company Delivery Hero SE, engineering group ABB Ltd. acquires flow technology company Rotork PLC, and Eli Lilly and Co. buys drug developer AtaiBeckley Inc.

  • July 14, 2026

    Goodwin Adds Life Sciences Veteran For San Diego Relaunch

    Goodwin Procter LLP announced on Tuesday that it had hired a veteran life sciences attorney to co-chair its new San Diego office, which is slated to open later this summer.

  • July 14, 2026

    AI Drug Discovery Biz Valued At $3.8B After Series C Round

    Artificial intelligence-based drug discovery company Chai Discovery on Tuesday revealed that it reached a $3.8 billion valuation after closing its latest funding round with $400 million in tow.

  • July 14, 2026

    BakerHostetler Flips Holland & Knight's Antitrust Co-Lead

    An attorney with nearly 25 years of experience in commercial and antitrust litigation has moved his practice to BakerHostetler's Philadelphia office after five years with Holland & Knight LLP.

  • July 13, 2026

    FTC Secures $12M Settlement Over Edwards-JC Medical Deal

    California-based Edwards Lifesciences and Singapore's Genesis Medtech agreed to pay a combined $12 million to settle claims from the Federal Trade Commission that Edwards attempted to evade the Hart-Scott-Rodino notification and waiting period when it acquired medical device maker JC Medical from Genesis in 2024.

  • July 10, 2026

    Taxation With Representation: Cleary, Paul Weiss, Fried Frank

    In this week's Taxation With Representation, Solstice Advanced Materials Inc. acquires specialty chemicals technology company Element Solutions Inc., Vertex Pharmaceuticals Inc. buys Crinetics Pharmaceuticals Inc., and Lockheed Martin acquires naval defense company Ultra Maritime.

  • July 09, 2026

    Regeneron Cites Medtronic Ruling In Amgen Bundling Case

    Regeneron has told a Delaware federal judge there is new reason to preserve its $407 million win against Amgen over cholesterol drug bundling after a California federal judge found in an analogous case that the plaintiff need not prove the defendant had monopoly power over every item in a bundle.

  • July 08, 2026

    Jazz Patent Suit Over Xyrem Survives Dismissal In NJ

    A New Jersey federal judge has refused to let generic-drug company Tris Pharma Inc. escape a suit claiming its attempt to sell a competing version of Jazz Pharmaceuticals' narcolepsy drug Xyrem infringes a series of patents.

  • July 08, 2026

    AstraZeneca Employee Traded On Icosavax Deal, SEC Says

    The U.S. Securities and Exchange Commission on Wednesday accused a former AstraZeneca Pharmaceuticals LP employee of using nonpublic information to trade ahead of the company's $1.1 billion acquisition of vaccine design company Icosavax Inc., yielding approximately $10,000 in illicit gains.

  • July 08, 2026

    Handa, Intas Face Patent Suits Over Exelixis Cancer Drug

    Handa Pharmaceuticals and Intas Pharmaceuticals are wrongly trying to bring to market drugs that would compete with Exelixis Inc.'s blockbuster cancer pill Cabometyx before patents on the medication expire, according to a new lawsuit in Delaware federal court.

  • July 08, 2026

    Biggest Rulings For Patent Attys In 2026: A Midyear Report

    The U.S. Supreme Court clarified the pleading standard for induced infringement of skinny labels, and the Federal Circuit opened the door to increased damages for patent owners. Here's what you need to know about these patent cases and other major decisions from the beginning of 2026.

  • July 07, 2026

    Align's Invisalign Patents Are Infringed But Invalid, Jury Finds

    A Texas federal jury has found that claims in four patents Invisalign maker Align Technology Inc. asserted against orthodontics company ClearCorrect were invalid, but the jurors also rejected ClearCorrect's antitrust claims against Align.

  • July 07, 2026

    Fed. Circ. Won't Revive Dental Patent Claims In Align Feud

    The Federal Circuit on Tuesday said it won't bring back claims in a pair of dental arch image analysis patents their owner accused Invisalign maker Align Technology Inc. of infringing, backing a lower court's finding that they were invalid.

  • July 06, 2026

    Clarivate Sells Life Sciences And Healthcare Biz For $600M

    Analytics company Clarivate PLC on Monday announced that it has agreed to sell its Life Sciences & Healthcare segment to investment firm Altaris LLC in a $600 million deal built by three law firms.

  • July 06, 2026

    NC Biz Court Bulletin: Rapid-Fire Rulings, Word Of Warning

    Summer is heating up in North Carolina Business Court with a slew of recent rulings, including one greenlighting a data breach class action brought by current and former workers who allege Charlotte-based Bojangles failed to guard their personal information from hackers.

  • July 06, 2026

    The Moments That Shaped The Monsanto Decision

    U.S. Supreme Court justices forged unusual alliances when they ruled a federal statute preempts claims Monsanto failed to warn consumers its Roundup weed killer may cause cancer. Oral arguments provided insights on the 7-2 outcome, highlighting issues the jurists were grappling with and showcasing rationales that found their way into the opinion.

  • July 06, 2026

    After Tense Terms, Hints Of High Court Harmony With Circuits

    Following several U.S. Supreme Court terms teeming with reversals and rebukes of lower appeals courts, the justices this term found fault less often with rulings by circuit judges, who are likely becoming better attuned to the conservative supermajority, attorneys say.

  • July 06, 2026

    The Funniest Moments Of The Supreme Court's Term

    When one of the U.S. Supreme Court's most talkative members suddenly struggled to speak, the atmosphere at oral arguments grew increasingly anxious — until the justice deadpanned that it was an advocate's golden opportunity to avoid a grilling.

Expert Analysis

  • How Maine's Expanded Health Deal Reviews Complicate M&A

    Author Photo

    A pair of recently approved Maine competition laws establish notice and approval requirements for certain healthcare transactions and expand state antitrust oversight, creating new hurdles for dealmakers as states take a more aggressive role in policing healthcare consolidation, especially involving private equity, say attorneys at McDermott.

  • Key Tips For Patenting Antibody-Drug Conjugate Inventions

    Author Photo

    Recent decisions highlight the significant challenges that can arise when patenting antibody-drug conjugates, which require strategic considerations for satisfying heightened written description and enablement requirements, says Xiaoban Xin at FisherBroyles.

  • 8 Ways 2026's Market Divide Is Rewriting Real Estate Risk

    Author Photo

    As construction activity increasingly concentrates in data centers, healthcare and other resilient sectors, real estate developers and their counsel in the second half of 2026 should consider earlier risk allocation and more protective contract terms, and expect greater pressure on labor, pricing and infrastructure, say attorneys at Cozen O'Connor.

  • A Midyear Look At Antiterrorism Act Jurisprudence And Policy

    Author Photo

    Plaintiffs have filed comparably fewer new actions under the Antiterrorism Act this year, though a handful of key decisions further defined the statute’s aiding-and-abetting standard and highlighted continuing risks for financial services companies, say attorneys at Skadden.

  • Risk Reduction Lessons For PE Firms From PowerSchool Suit

    Author Photo

    A California federal court's recent orders allowing claims against Bain Capital to proceed based on a data breach at its subsidiary PowerSchool indicate that private equity firms need to strategically approach acquisition activities to avoid cybersecurity risks, say attorneys at Womble Bond.

  • PowerSchool Data Breach Ruling Underscores PE Liability

    Author Photo

    The recent California federal court decision in PowerSchool, where Bain Capital was unable to dismiss claims relating to a data breach based in part on Bain's preinvestment activities, is an important addition to the line of cases addressing investor liability for acts of a portfolio company, says Mark Kelley at MoloLamken.

  • Calif. Case Raises Questions For Medical Practice Investors

    Author Photo

    The California attorney general's amicus brief in Art Center v. WCE and the California Medical Association's response highlight how the California appeals court's ruling could significantly affect the structure and enforceability of succession arrangements in medical practice ownership, say attorneys at Ropes & Gray.

  • How CMS Fraud Priorities Complicate Provider Acquisitions

    Author Photo

    As the Centers for Medicare & Medicaid Services steps up usage of its affiliates authority and post-transaction audits, parties contemplating the acquisition or sale of home health and hospice providers should take steps to avoid the potential suspension of Medicare billing privileges, say attorneys at Alston & Bird.

  • The Challenge Of Stabilizing Rural Hospitals On The Brink

    Author Photo

    The outlook for rural hospitals has grown more concerning, as recent policy and regulatory developments are decreasing hospital revenues and increasing the cost of uncompensated care, which may result in additional hospital closures, service reductions, or mergers and acquisitions, say Omur Celmanbet, Kristy Piccinini and Sabiha Quddus at FTI Consulting.

  • Bid Protest Spotlight: Evidence, Tailored Talks, Materiality

    Author Photo

    In this month's bid protest roundup, Brian Doll at MoFo delves into three recent decisions from the Government Accountability Office about the evidentiary standards necessary to sustain a protest, discussions tailored to individual proposals, and misrepresentation claims involving factors irrelevant to the agency's decision.

  • Senior Housing Demands A Distinct Dealmaking Playbook

    Author Photo

    An aging population and evolving state regulations underscore a critical reality that senior housing assets can undergo operational or compliance shifts during dealmaking, highlighting the need for unique contractual safeguards like expanded disclosures, anchored notice obligations, and targeted closing conditions and remedies, say attorneys at Goodwin.

  • OhioHealth Suit Signals Higher Antitrust Heat On Hospitals

    Author Photo

    The recent antitrust lawsuit against OhioHealth by the U.S. Justice Department and Ohio attorney general shows that federal and state enforcers are closely examining the competition issues in the healthcare sector, including restrictive contracts and antisteering practices, say attorneys at Freshfields.

  • What Changed For Healthcare Transaction Law In 2025

    Author Photo

    Though much of the legislation introduced last year to expand state scrutiny of healthcare transactions did not pass, investors should pay close attention to the overarching trends, which are likely to continue in this year's legislative sessions, say attorneys at Ropes & Gray.